Control Bionics
In December 2020, Control Bionics Limited (“Control Bionics”, ASX: CBL) listed on the ASX. Nightingale Partners Pty Ltd (“Nightingale”) first invested in Control Bionics in 2005 and continue to hold a minority stake in the company.
Control Bionics’ aim is to become the world’s leading provider of wearable, bionic assistive technology devices. Building on their successful NeuroNode EMG technology, they have recently released the NeuroNode Trilogy, a system combining their latest NeuroNode 3.0 device, with eye control and Grid 3 communication software, providing a lifetime solution for those with paralysis and loss of speech.
The funds raised in the IPO will assist Control Bionics in expanding their operations and sales, allowing them to provide their technology to people in need on a global scale.
Rob Wong, CEO of Control Bionics, was interviewed by ausbiz TV on the day of the listing to describe Control Bionics business to date and their focus moving forward. Link to the interview: https://www.ausbiz.com.au/media/in-control-and-going-for-global-growth-?videoId=5998